Core Laboratories account plan
Reservoir optimization services provider
At a glance
Core Laboratories provides reservoir description and production enhancement services to oil and gas companies, with $526.5 million revenue in FY2025.
Core Laboratories Inc. (Core Lab, NYSE: CLB), established in 1936 and a Delaware corporation since its May 1, 2023 redomestication from the Netherlands, provides proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry. It works mainly with major, national and independent oil companies, and also helps clients evaluate subsurface targets for Carbon Capture and Sequestration (CCS). It has over 70 offices in more than 50 countries and approximately 3,300 employees. FY2025 revenue was $526.5 million (+0.5%), 76% from services, with non-U.S. operations at 66%; operating income was $56.5 million and net income attributable to Core Laboratories Inc. $29.7 million.
Business units
Reservoir Description
66.0% of FY2025 revenue ($347.7 million)Laboratory and field analysis of reservoir rock and fluid samples and of crude oil and derived products, including crude assay work, plus CCS, geothermal and gas storage studies; about 80% of segment revenue comes from outside the U.S. Revenue was flat in 2025, and the segment bore the greatest impact of the 2026 Middle East conflict, with Q3 2026 revenue of $84.3 million (-4% year-over-year, +7% sequentially).
Production Enhancement
34.0% of FY2025 revenue ($178.8 million)Well completion diagnostics (frac water tracing, interference monitoring), perforating products made in the U.S. and Canada, and casing patches, mainly for U.S. unconventional plays plus conventional projects worldwide. Operating income rose 82% to $12.1 million in 2025, and Q3 2026 revenue reached $47.8 million (+3% year-over-year) on adoption of proprietary perforating products.
Strategic priorities
- New products in key markets
- The first strategic objective is "introducing new product and service offerings in key geographic markets", such as InPulse perforating, FLOWPROFILER and gas tracers, and SpectraStim and SpectraScan isotope diagnostics approved in the UAE.
- Lean organization and cost control
- Core Lab aims at "maintaining a lean and focused organization", cutting costs without losing experienced staff, with a cost reduction plan for the Russia-Ukraine business and facility consolidation.
- Free cash flow and shareholder returns
- The financial tenets are to maximize free cash flow and return on invested capital and return excess free cash; Q3 2026 was the eighth consecutive quarter of buybacks.
- International offshore and long-cycle projects
- Management expects a rebound in offshore reservoir characterization late in 2026 and into 2027, with activity picking up in Africa, Brazil and the South Atlantic margin, and Asia Pacific.
- Energy transition services
- CCS (including a CCS Consortium and a Q3 2026 project in Malaysia), geothermal, subsurface gas storage and appraisal of lithium and other energy-storage minerals.
Latest results
In Q3 2026 (quarter to September 30, 2026) revenue was $132.1 million, down 2% year-over-year and up 6% sequentially: services $96.0 million (-5%) and product sales $36.1 million (+8%). Operating income fell 42% to $12.1 million (9% margin), partly because Q3 2025 included a $5.3 million insurance recovery, and net income attributable to Core Laboratories Inc. was $5.4 million (-62%). Reservoir Description was hit by the Middle East conflict, the Strait of Hormuz disruption and Russia sanctions, while Production Enhancement grew on U.S. onshore perforating product sales. For the nine months revenue was $378.5 million (-3%). Q4 2026 guidance is revenue of $128.5-134.5 million and EPS of 12 to 20 cents.
Investments and deals
- Solintec acquisition
- Solintec, a Brazilian geological services company, was acquired on October 1, 2025 for $2.3 million upfront plus up to $3.7 million of contingent consideration over two years.
- Capex and facility rebuilds
- 2026 capex is guided at $14-16 million excluding the UK rebuild of the Aberdeen facility damaged by a February 2024 fire; capex was also raised by a multi-year Asia-Pacific contract and the rebuild of Mediterranean facilities damaged by weather.
- Debt refinancing
- The credit facility was renewed on July 22, 2025 at $150.0 million; $50.0 million was drawn on January 12, 2026 to repay the $45.0 million 2021 Senior Notes Series A. Debt stood at $114.8 million at September 30, 2026.
- Digital platforms
- The RAPID database, Advanced Rock Typing using AI image recognition, the CONNECT IT platform with client dashboards and a Digital Innovation Group, plus a new global human capital management system in 2025.
Challenges and risks
- Middle East conflict and Hormuz disruption
- The conflict that began on February 28, 2026 disrupted crude cargo movements, which Bruno said were "down 16% globally", cutting demand for laboratory assay services.
- Sanctions on Russia and Iran
- Expanded sanctions, including secondary sanctions on buyers of their crude, restrict work mainly in Russia and depress assay demand.
- Margin pressure
- Cost of services rose to 78% of service revenue in Q3 2026 (74% a year earlier) as costs were carried in conflict-affected regions, and inventory rose on raw-material cost increases.
- Exploration success and activity swings
- Rock and fluid projects were cancelled in 2025 after the international offshore exploration and appraisal success rate hit a 20-year low, and U.S. land product sales follow the rig count.
- Technology obsolescence
- The 10-K lists technology obsolescence, including from generative AI, alongside cyber security and retention of skilled technical staff.
What leadership says
“Reservoir Description bore the greatest impacts of the Middle East conflict as crude assay work and reservoir characterization projects depend on field operations, active maritime hydrocarbon trade and transportation, timely sample acquisition, and access to client facilities.”
“A global increase in capital spending is emerging across our conversations with our client base”
“to minimize costs without disassembling the experience and the staff that we have”
Where a supplier can help
- Cost efficiency in a lean organization
- The lean-organization priority and higher cost of services in conflict-affected regions make procurement, logistics and operating-cost tools relevant.
- Lab instrumentation and digital data
- Digital platforms such as RAPID, Advanced Rock Typing and CONNECT IT, plus the generative-AI obsolescence risk, open doors for data, AI and software partners.
- Facility rebuilds and capex
- Capex of $14-16 million in 2026, the Aberdeen rebuild and the Mediterranean facility repairs need construction, lab equipment and fit-out suppliers.
- Raw materials for perforating products
- Growing perforating product sales and higher raw material costs point to suppliers of materials and manufacturing services for the U.S. and Canada plants.
- Logistics for samples and international projects
- Reservoir work depends on timely sample acquisition and transport; logistics and field-operations support fits the offshore rebound in Africa, Brazil and Asia Pacific.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Core Laboratories?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Core Laboratories Inc. Annual Report on Form 10-K for fiscal year 2025
- Core Laboratories Inc. (Core Lab, NYSE: CLB), established in 1936 and a Delaware corporation since its May 1, 2023 redomestication from the Netherlands, provides proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry; over 70 offices in more than 50 countries and approximately 3,300 employees.
- FY2025 revenue was $526.5 million (+0.5%): services $399.4 million (76%) and product sales $127.1 million (24%); non-U.S. operations accounted for 66% of revenue.
- Two segments: Reservoir Description $347.7 million (66.0% of revenue, operating margin 12.6%) and Production Enhancement $178.8 million (34.0%, operating margin 6.7%).
- Operating income was $56.5 million (10.7% margin, down 3.6%); net income attributable to Core Laboratories Inc. was $29.7 million, diluted EPS $0.63; free cash flow $25.8 million.
- Reservoir Description was flat: higher international and crude-assay revenue was offset by cancelled rock and fluid projects after the success rate for international offshore exploration and appraisal wells hit a 20-year low.
- Production Enhancement operating income rose 82% to $12.1 million on growth in well completion diagnostic services as natural gas prices rebounded, while U.S. land product sales fell with the 6% drop in the land rig count.
- Debt was cut by $15.0 million (12%) to $113.0 million; $15.5 million of shares were bought back; dividend kept at $0.01 per quarter; the credit facility was renewed in July 2025 at $150.0 million.
- Acquired Solintec (Brazilian geological services) on October 1, 2025 for $2.3 million upfront plus up to $3.7 million contingent.
- Outlook (written March 2026): the US/Israel-Iran conflict from February 28, 2026 and the effective closure of the Strait of Hormuz raise uncertainty and directly affect laboratory assay demand; large international projects (Guyana, Suriname, Australia, West Africa, Middle East) seen as more resilient than U.S. short-cycle activity.
- Core Laboratories Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026) revenue was $132.1 million, down 2% year-over-year and up 6% sequentially: services $96.0 million (-5% YoY), product sales $36.1 million (+8% YoY, +19% QoQ).
- Operating income fell 42% YoY to $12.1 million (9% margin; Q3 2025 included a $5.3 million insurance recovery); net income attributable to Core Laboratories Inc. $5.4 million (-62%).
- Reservoir Description: $84.3 million (-4% YoY, +7% QoQ), operating income $7.7 million (9% margin vs 19%), hit by the Middle East Conflict, Strait of Hormuz disruption and Russia sanctions on assay work and regional studies.
- Production Enhancement: $47.8 million (+3% YoY), operating income $4.3 million (9%), driven by proprietary perforating product adoption on U.S. land; well diagnostics fell on delayed Gulf of America projects.
- Nine months 2026: revenue $378.5 million (-3%), operating income $23.1 million (-43%), free cash flow $5.4 million vs $20.8 million.
- Debt $114.8 million (a $50.0 million delayed draw term loan refinanced $45.0 million of notes in January 2026); leverage ratio 1.496; $81.6 million of facility capacity available.
- Outlook: crude supply still significantly disrupted although Hormuz traffic improved late in Q3; the Company expects increasing client activity in the coming years, with reserve replacement becoming an important topic.
- Core Laboratories Q2 2026 earnings call transcript
- Q2 2026 call (July 30, 2026), CEO Larry Bruno with CFO Chris Hill and IR head Gwen Gresham: revenue $124.6 million, up 2% sequentially and down 4% year-over-year; EPS ex items $0.11.
- Reservoir Description revenue $79 million (-4% QoQ, -9% YoY), margins 5%: Bruno says the segment "bore the greatest impacts of the Middle East conflict"; global crude cargo movements are "down 16% globally" versus pre-conflict.
- Production Enhancement revenue $46 million (+15% QoQ), margins 12% from 5%, on adoption of proprietary completion technologies (InPulse perforating, FLOWPROFILER and gas tracers).
- Wins: reservoir characterization after a successful Namibia offshore well, Murphy Oil's Cote d'Ivoire discovery (Dual Energy CT in Houston), and UAE approval for SpectraStim and SpectraScan isotope diagnostics.
- Strategy: new products in key markets, a lean organization, and returning excess free cash; 7th consecutive quarter of buybacks ($2.7 million).
- Cost stance: cut costs "without disassembling the experience and the staff"; a cost reduction plan is under way for the Russia-Ukraine business.
- Bruno sees "a very nice rebound in activity on offshore reservoir characterization projects late this year, but certainly into 2027"; Africa, Brazil/South Atlantic margin and Asia Pacific are picking up.
- Guidance Q3 2026: revenue $128.5-135.5 million, EPS $0.12-0.20; 2026 capex $15-18 million excluding the UK rebuild.
- Core Laboratories Q3 2026 earnings call transcript
- Q3 2026 call (October 29, 2026), CEO Larry Bruno, CFO Chris Hill, IR head Gwen Gresham: revenue $132.1 million, up 6% sequentially and down 2% year-over-year; EPS ex items $0.16 ($0.12 GAAP).
- Reservoir Description revenue $84.3 million (+7% QoQ), margins ex items 10% from 5%, with 78% incremental margins; still hurt by Hormuz-related assay declines and Russia-Ukraine sanctions.
- Production Enhancement revenue $47.8 million (+4% QoQ), margins over 9% (12% in Q2) as product sales outgrew diagnostics; Gulf of America diagnostic projects slipped into Q4.
- Wins: a CCS project in Malaysia, an offshore mobile laboratory for a Black Sea development, a five-year water shutoff contract with a Southeast Asian NOC, and tracer diagnostics for a Middle East unconventional development.
- 8th consecutive quarter of buybacks (about 88,000 shares, $1.1 million); net debt $93.4 million, leverage just under 1.5; 2026 capex $14-16 million excluding the UK rebuild.
- Q4 2026 guidance: revenue $128.5-134.5 million (relatively flat), EPS of 12 to 20 cents.
- Bruno: "A global increase in capital spending is emerging across our conversations with our client base"; the U.S. land uptick comes from smaller and private operators.
Questions about Core Laboratories
What does Core Laboratories do?
Core Lab provides proprietary reservoir description and production enhancement services and products to the oil and gas industry, measuring reservoir rocks and fluids and supplying well completion diagnostics and perforating products. It also evaluates subsurface targets for CCS.
What is Core Laboratories' revenue?
FY2025 revenue was $526.5 million (+0.5%). Q3 2026 revenue was $132.1 million, and nine-month 2026 revenue $378.5 million.
How many employees does Core Laboratories have?
Approximately 3,300 employees across over 70 offices in more than 50 countries.
Who leads Core Laboratories?
Lawrence (Larry) Bruno is Chairman, President and Chief Executive Officer; Christopher S. Hill is Senior Vice President and Chief Financial Officer.
What is Core Laboratories' strategy?
New product and service offerings in key geographic markets, a lean and focused organization, and returning excess free cash while preserving the balance sheet.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)